Optimi Health (TSE:OPTI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Optimi Health Corp. has received three export permits from Health Canada to begin supplying its GMP-compliant MDMA and psilocybin capsules to Australia, marking the company’s first commercial venture into the country. These capsules are intended for the treatment of PTSD and Treatment-Resistant Depression under Australia’s Authorised Prescriber Scheme. The move follows Australia’s reclassification of these substances for regulated medical use and is seen as a significant step in the global supply of psychedelic-assisted therapies.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.